PROVEN RESULTS IN mHSPC
*NUBEQA combination=NUBEQA + hormone therapy with docetaxel (chemotherapy).
Men with mHSPC who added NUBEQA to hormone therapy† + docetaxel (chemotherapy)‡ had a
32% lower risk of dying than men who only received hormone therapy + chemotherapy.
Another way to look at the results:
In the study for mHSPC, more men who added NUBEQA to hormone therapy + docetaxel (chemotherapy)
were still alive at 4 years compared with men who only received hormone therapy + chemotherapy.
†Hormone therapy includes drug treatments or surgery to lower testosterone.‡Docetaxel is an intravenous (IV) chemotherapy infusion used in combination with NUBEQA to treat mHSPC. mHSPC=metastatic hormone-sensitive prostate cancer, a type of prostate cancer that has spread to other parts of the body and still responds to hormone therapy.
How NUBEQA was studied in mHSPC
The NUBEQA combination was compared with hormone therapy + docetaxel
(chemotherapy) in a clinical study of 1305 men with mHSPC
Overall, adding NUBEQA to hormone therapy + chemotherapy reduced the risk of
pain getting worse by 21%.